Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.

Journal Article (Journal Article)

PURPOSE: The use of combined estrogen-progestin menopausal hormone therapy (MHT) has been shown to increase the risk of breast cancer, however, recent observational studies have suggested that the association between MHT and breast cancer may be modified by race. The objective of this study was to investigate the association between MHT use and incidence of invasive breast cancer in Black and White women aged ≥40 years at diagnosis after accounting for racial differences in patterns of MHT use and formulation. METHODS: Data from the Carolina Breast Cancer Study, a population-based case-control study of Black and White women in North Carolina conducted between 1993 and 2001, was used to analyze 1474 invasive breast cancer cases and 1339 controls using unconditional logistic regression. RESULTS: Black women were less likely than White women to use any MHT and were more likely to use an unopposed-estrogen formulation. Combined estrogen-progestin MHT use was associated with a greater odds of breast cancer in White (adjusted odds ratio [OR] 1.48, 95% confidence interval [CI]: 1.03-2.13) and Black (OR 1.43, 95% CI: 0.76-2.70) women, although the estimate in Black women was imprecise. In contrast, use of unopposed-estrogen MHT among women with prior hysterectomy was not associated with breast cancer in women of either race. CONCLUSION: The association between MHT and invasive breast cancer appears to be similar in both Black and White women after accounting for differences in formulation and prior hysterectomy. These findings emphasize the importance of accounting for MHT formulation in race-stratified analyses of breast cancer risk.

Full Text

Duke Authors

Cited Authors

  • DeBono, NL; Robinson, WR; Lund, JL; Tse, CK; Moorman, PG; Olshan, AF; Troester, MA

Published Date

  • March 2018

Published In

Volume / Issue

  • 27 / 3

Start / End Page

  • 377 - 386

PubMed ID

  • 28570827

Pubmed Central ID

  • PMC5865240

Electronic International Standard Serial Number (EISSN)

  • 1931-843X

Digital Object Identifier (DOI)

  • 10.1089/jwh.2016.6063


  • eng

Conference Location

  • United States